Literature DB >> 20626397

Potential role for vascular endothelial growth factor-D as an autocrine factor for human gastric carcinoma cells.

Miwako Tanaka1, Yasuhiko Kitadai, Michiyo Kodama, Kei Shinagawa, Tomonori Sumida, Shinji Tanaka, Naohide Oue, Wataru Yasui, Kazuaki Chayama.   

Abstract

Vascular endothelial growth factor (VEGF)-D induces lymphangiogenesis by activating VEGF receptor (VEGFR)-3, which is expressed mainly by lymphatic endothelial cells. VEGFR-3 has also been detected in several types of malignant cells, but the significance of VEGFR-3 expression by malignant cells remains unclear. We examined the expression and function of VEGF-D/VEGFR-3 in human gastric carcinoma cells. Expression of VEGF-D and VEGFR-3 was analyzed in three human gastric carcinoma cell lines and 29 surgical specimens. cDNA microarray analysis was used to examine the effect of VEGF-D on the expression of genes associated with disease progression in VEGFR-3-expressing KKLS cells. VEGF-D-transfected cells and control cells were transplanted into the gastric wall of nude mice. In 10 of the 29 (34%) gastric carcinoma specimens and two of the three cell lines, cancer cells expressed both VEGF-D and VEGFR-3. In vitro treatment of KKLS cells with exogenous VEGF-D increased expression of cyclin D1 and Bcl-2 and stimulated cell proliferation. VEGF-D transfection into KKLS cells resulted in stimulation of angiogenesis, lymphangiogenesis, and cell proliferation, and in inhibition of apoptosis. VEGF-D may participate in the progression of human gastric carcinoma by acting via autocrine and paracrine mechanisms.
© 2010 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20626397     DOI: 10.1111/j.1349-7006.2010.01649.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  4 in total

1.  Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.

Authors:  Jill M Siegfried; Christopher T Gubish; Mary E Rothstein; Cassandra Henry; Laura P Stabile
Journal:  J Thorac Oncol       Date:  2012-03       Impact factor: 15.609

2.  Primary Tumor-Secreted Lymphangiogenic Factors Induce Pre-Metastatic Lymphvascular Niche Formation at Sentinel Lymph Nodes in Oral Squamous Cell Carcinoma.

Authors:  Naohiro Wakisaka; Yasuhisa Hasegawa; Seiichi Yoshimoto; Kouki Miura; Akihiro Shiotani; Junkichi Yokoyama; Masashi Sugasawa; Makiko Moriyama-Kita; Kazuhira Endo; Tomokazu Yoshizaki
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

3.  VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance.

Authors:  Signe R Michaelsen; Mikkel Staberg; Henriette Pedersen; Kamilla E Jensen; Wiktor Majewski; Helle Broholm; Mette K Nedergaard; Christopher Meulengracht; Thomas Urup; Mette Villingshøj; Slávka Lukacova; Jane Skjøth-Rasmussen; Jannick Brennum; Andreas Kjær; Ulrik Lassen; Marie-Thérése Stockhausen; Hans S Poulsen; Petra Hamerlik
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

4.  RNF180 mediates STAT3 activity by regulating the expression of RhoC via the proteasomal pathway in gastric cancer cells.

Authors:  Zizhen Wu; Huifang Liu; Weilin Sun; Yingxin Du; Wenting He; Shiwei Guo; Liqiao Chen; Zhenzhen Zhao; Pengliang Wang; Han Liang; Jingyu Deng
Journal:  Cell Death Dis       Date:  2020-10-20       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.